GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00311506
Cathflo Activase Pediatric Study
Phase 4
Completed
- Conditions
- Dysfunctional Central Venous Access Devices (CVADS)
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00307580
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 755
- Registration Number
- NCT00299104
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 511
- Registration Number
- NCT00299130
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00287716
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT00287729
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Tetanus toxoid adsorbed booster vaccineBiological: C. albicansBiological: 23-valent pneumococcal polysaccharide vaccineBiological: Keyhole limpet hemocyanin
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00282308
- Locations
- 🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States
🇺🇸Borgess Research Institute, Kalamazoo, Michigan, United States
🇺🇸Justus Fiechtner MD - PP, Lansing, Michigan, United States
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Phase 3
Completed
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT00282347
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
Phase 3
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 684
- Registration Number
- NCT00281697
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00272415
© Copyright 2025. All Rights Reserved by MedPath